Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-36333
Volltext verfügbar? / Dokumentlieferung
Titel: Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial
VerfasserIn: Böhm, Michael
Slawik, Jonathan
Brueckmann, Martina
Mattheus, Michaela
George, Jyothis T
Ofstad, Anne Pernille
Inzucchi, Silvio E
Fitchett, David
Anker, Stefan D
Marx, Nikolaus
Wanner, Christoph
Zinman, Bernard
Verma, Subodh
Sprache: Englisch
Titel: European Journal of Heart Failure
Bandnummer: 22
Heft: 1
Seiten: 126-135
Verlag/Plattform: Wiley
Erscheinungsjahr: 2019
Freie Schlagwörter: Diabetes
Empagliflozin
Heart failure
Mortality
Oedema
SGLT2 inhibitors
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Aims Atrial fibrillation (AF) is common in patients with diabetes and heart failure (HF) and increases the future risk of adverse cardiovascular (CV) outcomes. This analysis from the EMPA-REG OUTCOME trial explores CV and renal outcomes in patients with vs. without AF at baseline and assesses the benefits of empagliflozin. Methods and results Analyses were conducted on patients distinguished by the presence (n = 389) or absence (n = 6631) of AF at baseline. Outcome events were more frequent in patients with AF than those without AF. Empagliflozin compared to placebo reduced CV death or HF hospitalisation consistently in patients with AF [hazard ratio (HR) 0.58, 95% confidence interval (CI) 0.36–0.92] and without AF (HR 0.67, 95% CI 0.55–0.82, Pinteraction = 0.56). Similar results were observed for the components of this endpoint, all-cause mortality, new or worsening nephropathy, first introduction of loop diuretics, or occurrence of oedema. The absolute number of prevented events was higher in patients with AF, resulting in larger absolute treatment effects of empagliflozin. New loop diuretics or oedema were associated with increased rates of subsequent events, and rates appeared lower in those randomised to empagliflozin. Conclusions In patients with type 2 diabetes mellitus and established CV disease, those with AF at baseline had higher rates of adverse HF outcomes than those without AF. Irrespective of the presence of AF, empagliflozin reduced HF-related and renal events. The absolute number of prevented events is higher in patients with AF than without AF. Patients with diabetes, CV disease and AF may especially benefit from use of empagliflozin.
DOI der Erstveröffentlichung: 10.1002/ejhf.1663
URL der Erstveröffentlichung: https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1663
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-363331
hdl:20.500.11880/32999
http://dx.doi.org/10.22028/D291-36333
ISSN: 1879-0844
1388-9842
Datum des Eintrags: 2-Jun-2022
Bezeichnung des in Beziehung stehenden Objekts: Supporting Information
In Beziehung stehendes Objekt: https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fejhf.1663&file=ejhf1663-sup-0001-TableS1.docx
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Innere Medizin
Professur: M - Prof. Dr. Michael Böhm
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Es gibt keine Dateien zu dieser Ressource.


Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt.